Drugs / Arepanrix
last change Jun 2026 re-read 2 minutes ago

Arepanrix

also known as GSK2340274A

Vaccine

Developed for
swine influenza · influenza · avian influenza
Investigated by
Canadian Institutes of Health Research (CIHR) · David Scheifele · GlaxoSmithKline · PHAC/CIHR Influenza Research Network

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) Arepanrix 2010-12-13 europa.eu
Approved · conditional EU (EMA) Arepanrix 2010-03-23 europa.eu

Trials 3 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT01114620 May → Nov 2010 influenza GlaxoSmithKline Completed No outcome recorded
Phase 4 NCT01001026 Nov 2009 → Feb 2010 swine influenza David Scheifele Completed No outcome recorded
Phase 4 NCT01000584 Nov 2009 → Feb 2010 swine influenza David Scheifele Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT07240558 Comparator Nov 2025 → Jun 2026 overdue avian influenza University Health Network, Toronto Recruiting No outcome recorded
Phase 43 trials
Phase 4 NCT07275060 Comparator Oct 2025 → Feb 2027 expected avian influenza Canadian Immunization Research Network Active not recruiting No outcome recorded
Phase 4 NCT01002040 Comparator Feb → Jul 2010 HIV infectious disease, swine influenza University of British Columbia Completed No outcome recorded
Phase 4 NCT01000831 Comparator Nov 2009 → Feb 2010 influenza University of British Columbia Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Arepanrix ClinicalTrials.gov intervention name — accepted as the source's own label NCT01114620
6

NCT01000831

NCT01000584

NCT07275060

NCT01001026

NCT01002040

NCT07240558

Known as GSK2340274A “GSK Biologicals' Influenza Vaccine Arepanrix™ (GSK2340274A)” NCT01114620
Modality Vaccine “ASO3-adjuvanted H1N1(2009) vaccinePMID 21178654 May 2011
Route Intramuscular “Adults: One dose Arepanrix vaccine given IM (0.5 mL)” NCT01001026